ALPHAEON Corp, Irvine, Calif, chose the recent American Society of Aesthetic Plastic Surgery meeting in Las Vegas to share its positive findings regarding two phase III clinical trials.
Trials of ALPHAEON’s DWP-450 botulinum type A neuromodulator focused on the treatment of glabellar, or frown lines, between the eyebrows. The randomized, placebo-controlled, multi-center, double blind trials were able to substantiate a least a 2-point improvement 30 days after the treatment.
Researchers compared these findings to pre-treatment, baseline findings. The double blind trials (EV001 and EV002) achieved a 67.5% success rate in the EV001 study and 70.4% in the EV002 study. Each proved statistically superior to the placebo control groups, according to a media release from ALPHAEON.
“The results of our phase III clinical trials marks a significant milestone for ALPHAEON,” states Chris Marmo, president of Beauty, ALPHAEON, in the release. “It’s a great advancement in the regulatory process, and we look forward to leveraging our unique and innovative social commerce platform to offer this product to board certified specialty physicians.”
Additional study information is available at www.clinicaltrials.gov, clinical trial identifiers NCT02334423 and NCT02334436.
[Source(s): ALPHAEON Corp, PR Newswire]